Doprava zadarmo od 24,99 €. Viac info.
Bookbot

New Developments in Biosciences - 4: Endocrine Management of Prostatic Cancer

Parametre

  • 143 stránok
  • 6 hodin čítania

Viac o knihe

This work explores the intricate mechanisms of hormonal action at the cellular level, focusing on androgen withdrawal therapies and their effects on human testis tissue. It discusses the target-cell responses to androgen withdrawal and highlights the significance of animal models, particularly the nude mice model, in studying human prostatic carcinoma. The etiology and natural history of early prostatic cancer are examined, alongside the pharmacological basis for androgen deprivation using various antiandrogens in combination with LH-RH agonists. In the clinical section, the evaluation of different endocrine approaches for treating prostatic carcinoma is presented, along with the rationale for total androgen blockade using cyproterone acetate. Clinical experiences with Androcur® and the tolerance of various endocrine regimens are discussed, providing insights into long-term treatment outcomes with cyproterone acetate in advanced cases. Current trends in androgen ablation therapy in the USA are reviewed, alongside long-term results of LH-RH agonist monotherapy in prostate carcinoma patients. This comprehensive examination includes contributions from various experts in the field, offering a detailed understanding of the complexities involved in prostate cancer treatment.

Nákup knihy

New Developments in Biosciences - 4: Endocrine Management of Prostatic Cancer, Herbert Klosterhalfen

Jazyk
Rok vydania
1988
Väzba
(pevná),
Stav knihy
Dobrá
Cena
4,49 €

Doručenie

  • Doprava zadarma od 24,99 € po celom Slovensku! Viac info

Platobné metódy

Nikto zatiaľ neohodnotil.Ohodnotiť

Titul
New Developments in Biosciences - 4: Endocrine Management of Prostatic Cancer
Jazyk
anglicky
Vydavateľ
De Gruyter
Rok vydania
1988
Väzba
pevná
Počet strán
143
ISBN10
3110115131
ISBN13
9783110115130
Série
Anotácia
This work explores the intricate mechanisms of hormonal action at the cellular level, focusing on androgen withdrawal therapies and their effects on human testis tissue. It discusses the target-cell responses to androgen withdrawal and highlights the significance of animal models, particularly the nude mice model, in studying human prostatic carcinoma. The etiology and natural history of early prostatic cancer are examined, alongside the pharmacological basis for androgen deprivation using various antiandrogens in combination with LH-RH agonists. In the clinical section, the evaluation of different endocrine approaches for treating prostatic carcinoma is presented, along with the rationale for total androgen blockade using cyproterone acetate. Clinical experiences with Androcur® and the tolerance of various endocrine regimens are discussed, providing insights into long-term treatment outcomes with cyproterone acetate in advanced cases. Current trends in androgen ablation therapy in the USA are reviewed, alongside long-term results of LH-RH agonist monotherapy in prostate carcinoma patients. This comprehensive examination includes contributions from various experts in the field, offering a detailed understanding of the complexities involved in prostate cancer treatment.